Condition: Recurrent World Health Organization (WHO) Grade II Glioma · Low-grade Glioma · High Grade Glioma · Sponsor: University of California, San Francisco
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.
This description comes directly from the study's public registry record.
PNOC Operations · 415-502-1600 · PNOC021@ucsf.edu
Sabine Mueller, MD, PhD, MAS · 877-827-3222 · cancertrials@ucsf.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham, Children's of Alabama | Birmingham, Alabama, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California, San Diego Rady Children's Hospital | San Diego, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
| John Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Withdrawn |
| Children's Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04485559